1. Karyopharm to present in Baird's Biotech Discovery Series on December 10. 2. Dr. Claire Harrison, an expert, will participate in the fireside chat. 3. Karyopharm focuses on innovative cancer therapies, including XPOVIO. 4. XPOVIO is approved in the U.S. and several international markets. 5. The company has multiple targets in high unmet need cancers.
FAQ
Why Bullish?
The participation in a prestigious event highlights KPTI's credibility and growth prospects.
How important is it?
The announcement emphasizes KPTI's engagement and strategic positioning in the biotech sector.
Why Short Term?
Immediate interest may arise from the upcoming event, with potential short-term stock movements.
Karyopharm (KPTI) to Engage in Baird's Biotech Discovery Series
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leading pharmaceutical company at the forefront of cancer therapy innovation, announced today that its senior management team and esteemed expert Dr. Claire Harrison will participate in a virtual fireside chat during Baird's Biotech Discovery Series. This event is scheduled for Wednesday, December 10, 2025, at 12:00 p.m. ET.
Event Details and Access
The virtual chat will feature insights from Dr. Harrison, who serves as the Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust. Renowned for her expertise in myelofibrosis, Dr. Harrison is expected to share valuable perspectives on advancements in the treatment of the disease.
Investors and interested parties can access a live webcast of this important event on the Karyopharm website under the "Events & Presentations" section. A replay of the discussion will also be made available after the event concludes.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI) is committed to pioneering novel cancer therapies that empower patients battling this challenging disease. Established with a strong belief in patient resilience, Karyopharm has emerged as a leader in developing oral therapeutic agents that rectify nuclear export dysregulation, an underlying cause of oncogenesis.
- The company's flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor.
- XPOVIO® is currently approved for use in three oncology indications in the United States.
- The medication holds regulatory approvals in over 50 ex-U.S. territories, including the European Union, the United Kingdom (as NEXPOVIO®), and China.
Karyopharm continues to focus on a robust pipeline aimed at addressing high unmet needs in various cancer types, notably in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
For further information on Karyopharm's work, visit www.karyopharm.com, and engage with them on LinkedIn or X at @Karyopharm.
Conclusion
As a commercial-stage company listed on Nasdaq under the symbol KPTI, Karyopharm Therapeutics is poised to continue its impactful journey in cancer treatment innovation. The upcoming participation in Baird's Biotech Discovery Series signifies Karyopharm's commitment to advancing cancer therapies and enhancing patient outcomes.